SK pharmteco invests $260 million in small molecule and peptide manufacturing capacity

– Expansion of a new 5-stöckiges, 136 Quadratfuß großes Mehrzweckgebäude in Sejong

– More than 300 new workers will be planted in January 2026.

RANCHO CORDOVA, California, September 30, 2024–(BUSINESS WIRE)–SK pharmteco, a world-class technology development and production company (CDMO), has developed a significant production facility for small molecules and peptides during a $260 million investment to build a new facility new high modern Anlage in Sejong, South Korea, bekannt.

The new edition, the end of 2026 in the Betrieb community, became so nice that the Unternehmen in South Korea were eroffnet, and there was an Eckpfeiler from the global production network of SK pharmaceutical companies. On a scale of 135,800 Quadratfuß, eight production lines are added and a yearly production of more Dutzend Tonen ermöglichen. This investment is one of the most advanced F&E facilities for peptides, cGMP kilo laboratories and a cGMP pilot for the peptide recovery lung. These sources can promote clinical production in the früh stage as well as commercial production with greater flexibility.

Schließlich de Investition auch de Bau des Rohbaus für eine sechste Produktionsstätte, die is een ermöglichen wird, unsere Kapazitäten in Zukunft schnell zu erweitern.

“Diese Erweiterung is a Beweis für unser unermüdliches Engagement, which in itself walks the business of the Life-Science-Branche zu erüllen,” says Joerg Ahlgrimm, CEO of SK pharmteco. global expansion strategy and developing a position as an external therapies partner, committed to developing high quality and care in one of the short-changing industries under Beweis.”

SK pharmteco plans the installation of über 300 new Mitarbeitern am Standort Sejong, an extension of the expansion. The investment in the involvement of SK pharmteco, which conducts research into high peptides and small molecular compounds, is likely to provide these scientific compounds with innovative therapies and further our care and commitment to the industry.

The Life Science Industry has carried out rapid research, which is supported by technological development and an increasing trend towards innovative therapy. The global concern for these therapies is focused on recovery, expanding production capabilities and complex regulatory interventions. The new research of SK pharmaceuticals with the herausforderungsrecht, compensates for a scalable and neglected loss for the recovery that the therapeutic treatment offers.

Read on